February 19, 2025 C-Path’s eCOA Consortium Welcomes Veeva Systems and VPG Health as Newest Partners C-Path's eCOA Consortium is thrilled to welcome Veeva Systems and VPG Health...
February 18, 2025 C-Path’s CPA-1 Consortium Welcomes Newest Members Kamada, Sanofi Critical Path for Alpha-1 (CPA-1) consortium today announced the addition of biopharmaceutical companies, Kamada...
February 1, 2025 Increased discoverability of rare disease datasets through knowledge graph integration Healthcare datasets can be used for many different purposes in the pursuit of...
January 28, 2025 TRxA Funding Opportunities 2025 On January 28, C-Path’s Translational Therapeutics Accelerator (TRxA)...
February 20, 2025 Vivli and RDCA-DAP Present: Data Platform Partnerships to Promote Rare Disease Data Sharing Join Julie Wood, Chief Operating Officer at Vivli, for an engaging webinar, Thursday, February 20, where she’ll discuss...
January 21, 2025 Save the Date: CGIC Returns to D.C. this September We are thrilled to invite you to the 2025 Critical Path Institute® (C-Path) Global Impact Conference (CGIC)...
January 7, 2025 Inclusion in neurological research: empowering people living with neurological diseases The value of involving people living with diseases in the research process is increasingly recognized...
December 12, 2024 Investigating item response theory model performance in the context of evaluating clinical outcome assessments in clinical trials Item response theory (IRT) models are an increasingly popular method choice for...
November 27, 2024 A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials...
December 1, 2024 Advancing rare disease measurement through the Rare Disease Clinical Outcome Assessment Consortium Naomi Knoble, and Lindsey T. Murray on behalf of the Rare Disease Clinical Outcome Assessment Consortium. View all...
